Physician profile
John D Fenley
NPI 1568537751
$1,370,446.47
in general payments reported to CMS, 2019-2025
28 companies · $316K in 2025
The $316K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139K · 2020: $109K · 2021: $104K · 2022: $160K · 2023: $250K · 2024: $291K · 2025: $316K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $550K · Consulting Fee: $107K · Honoraria: $105K · Travel and Lodging: $75K · Food and Beverage: $21K · Education: $8.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $549,678.25 |
| Consulting Fee | $107,140.00 |
| Honoraria | $104,600.00 |
| Travel and Lodging | $75,498.65 |
| Food and Beverage | $20,756.07 |
| Education | $8.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $478,826.58 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $423,203.81 | 2019-2025 | Rexulti, Nuedexta |
| Axsome Therapeutics, INC. | $223,098.53 | 2022-2025 | Auvelity, Sunosi, Symbravo |
| Allergan, INC. | $166,840.37 | 2019-2021 | |
| Abbvie INC. | $43,056.06 | 2021-2025 | |
| Alkermes, INC. | $18,777.67 | 2021-2025 | Lybalvi |
| Sunovion Pharmaceuticals INC. | $7,869.05 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $3,058.59 | 2019-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $1,046.91 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $916.57 | 2019-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $825.49 | 2019-2024 | Austedo Xr, Uzedy |
| Lundbeck LLC | $514.98 | 2019-2025 | Rexulti, Abilify Maintena |
| Bausch Health US, LLC | $504.17 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $467.73 | 2022-2025 | Quviviq, Quviviq |
| Janssen Pharmaceuticals, INC | $457.83 | 2019-2025 | Spravato |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $189.92 | 2022-2023 | Qelbree |
| Merck Sharp & Dohme LLC | $125.92 | 2020-2023 | Belsomra |
| Tris Pharma INC | $123.69 | 2023-2024 | Dyanavel Xr |
| Eisai INC. | $109.67 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $106.99 | 2024-2025 | Cobenfy |
| Acadia Pharmaceuticals INC | $97.13 | 2021 | |
| Almatica Pharma LLC | $71.65 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $64.10 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $31.63 | 2019-2023 | Jornay Pm |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21.96 | 2023 | Aplenzin |
| Adlon Therapeutics L.P. | $15.67 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.38 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Fenley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.